LIA VILARDO: Open Payments
NPI 1093595605 · EDGEWOOD, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,230 in 23 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $751 · 2025 $1,230
Food & beverage: $1,230
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $443 |
| Penumbra, Inc. | 1 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $144 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| PFIZER INC. | 1 | $120 |
| Novo Nordisk Inc | 1 | $89 |
| Novartis Pharmaceuticals Corporation | 4 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| GlaxoSmithKline, LLC. | 1 | $19 |
Products named: REPATHA, Penumbra System, Kerendia, UPTRAVI, VYNDAQEL, Ozempic, LEQVIO, JARDIANCE.
Industry payments across KY — which companies pay providers there.
